PPARA and primary biliary cholangitis: IBAT inhibitors in PBC are intended to reduce cholestatic pruritus by blocking ileal reabsorption of BAs; these agents have not shown disease-modifying biochemical benefits comparable to FXR/PPAR agonists and are positioned for symptom control rather than disease-modifying agents (Hegade et al., 2017).